within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX03_Nateglinide;

model Nateglinide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.72,
    Cl = 5.000000000000001e-07,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.009300000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.035,
    Tlag = 600,
    Vdp = 0.0162,
    k12 = 1.1944444444444443e-06,
    k21 = 1.1944444444444443e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Nateglinide</td></tr><tr><td>ATC code:</td><td>A10BX03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Nateglinide is a rapid-acting oral hypoglycemic agent belonging to the meglitinide class used in the treatment of type 2 diabetes mellitus. It stimulates insulin release from pancreatic beta cells and is approved for glycemic control used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=\"https://doi.org/10.2165/00003088-200544120-00002\">10.2165/00003088-200544120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16372821/\">https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2004). Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. <i>Clinical pharmacokinetics</i> 43(4) 267–278. DOI:<a href=\"https://doi.org/10.2165/00003088-200443040-00005\">10.2165/00003088-200443040-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15005635/\">https://pubmed.ncbi.nlm.nih.gov/15005635</a></p></li><li><p>Cheng, Y, et al., &amp; Zhou, HH (2013). Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. <i>European journal of clinical pharmacology</i> 69(3) 407–413. DOI:<a href=\"https://doi.org/10.1007/s00228-012-1364-9\">10.1007/s00228-012-1364-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22842957/\">https://pubmed.ncbi.nlm.nih.gov/22842957</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Nateglinide;
